4//SEC Filing
MCCORMICK FRANK 4
Accession 0001257809-25-000003
CIK 0001743881other
Filed
Sep 7, 8:00 PM ET
Accepted
Sep 8, 6:06 PM ET
Size
537.6 KB
Accession
0001257809-25-000003
Insider Transaction Report
Form 4
MCCORMICK FRANK
Director
Transactions
- Exercise/Conversion
Common Stock
2025-09-05$11.92/sh+74,000$882,080→ 157,275 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-09-05−74,000→ 84,814 totalExercise: $11.92Exp: 2033-02-20→ Common Stock (74,000 underlying) - Sale
Common Stock
2025-09-05$53.16/sh−74,000$3,933,544→ 83,275 total
Holdings
- 879,979(indirect: By Trust)
Common Stock
Footnotes (2)
- [F1]Represents the weighted average sale price of the shares sold from $52.96 to $53.39 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F2]The stock option vests and becomes exercisable in three annual installments after February 21, 2023, with a final vesting date of February 21, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date.
Issuer
BridgeBio Pharma, Inc.
CIK 0001743881
Entity typeother
Related Parties
1- filerCIK 0001257809
Filing Metadata
- Form type
- 4
- Filed
- Sep 7, 8:00 PM ET
- Accepted
- Sep 8, 6:06 PM ET
- Size
- 537.6 KB